$ADXS Selected for Inclusion in Russell Global and Russell 3000® Indexes


Advaxis Selected for Inclusion in Russell Global and Russell 3000® Indexes

Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the company will be added to the Russell Global and Russell 3000® Indexes. This inclusion will become effective upon the close of trading on June 26, when the Russell Investment Group reconstitutes its comprehensive set of U.S. and global indexes, according to a preliminary list of additions posted on June 12.

“We are pleased to be added to the Russell Global and 3000 indexes, which reflects our overall efforts to increase shareholder value,” said Gregory T. Mayes, Executive Vice President and COO of Advaxis. “We expect our inclusion will raise the profile of Advaxis and generate additional interest in our proprietary cancer immunotherapy product candidates.”

Membership in the Russell 3000® Index means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. The Russell 3000® Index encompasses the 3,000 largest U.S.-traded stocks by objective, market-capitalization rankings and style attributes. This weighted index by market capitalization was constructed to provide a comprehensive barometer of the broad market and it now represents approximately 98 percent of the investable U.S. equity market. The Russell Global Indexes reflect the performance of over 10,000 securities in 47 countries. Membership in these indexes is updated annually, and remains in place for one year.

About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The LmTechnology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’s lead Lm Technology immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted Advaxis orphan drug designation for each of these three indications. For additional information on Advaxis, visitwww.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Forward-Looking Statements
This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis’s ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’s proprietary immunotherapy, ADXS-HPV. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’s SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2014, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Previous article$BLUE Form 8-K
Next article$CUR Form 8-K


Please enter your comment!
Please enter your name here